Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein

Journal of Alternative and Complementary Medicine

Volumn 14, Issue 3, 2008, Pages 287-297

  Wang, Stephen W J ^a   Chen, Yan ^b   Joseph, Tiby ^a   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Jiangsu Provincial Academy of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHANIN A; DAIDZEIN; DIPYRIDAMOLE; FORMONONETIN; GENISTEIN; ISOFLAVONE;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PERMEABILITY; PRIORITY JOURNAL; RED CLOVER;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENISTEIN; HUMANS; INTESTINAL ABSORPTION; ISOFLAVONES; TRIFOLIUM;

EID: 42049115114     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2007.0617     Document Type: Article

References (23)

1. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17:353-381.
2. Lamartiniere CA. Protection against breast cancer with genistein: A component of soy. Am J Clin Nutr 2000;71(Suppl 6):1705S-1707S; discussion, 1708S-1709S.
3. Muthyala RS, Sheng S, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor. J Med Chem 2003;46:1589-1602.
4. Setchell KD, Cassidy A. Dietary isoflavones: Biological effects and relevance to human health. J Nutr 1999;129:758S-767S.
5. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacol Ther 2001;90:157-177.
6. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 2001;21:381-406.
7. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000;55:481-504.
8. Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998;83:2223-2235.
9. Messina MJ. Legumes and soybeans: Overview of their nutritional profiles and health effects. Am J Clin Nutr 1999;70(3suppl):439S-450S.
10. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Contr 1998;9:553-557.
11. Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, Hernandez L, Goetz A, Llorens V, Lieberman R, Crowell JA, Poisson BA, Bergan RC. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1213-1221.
12. Crowell JA. The chemopreventive agent development research program in the Division of Cancer Prevention of the U.S. National Cancer Institute: An overview. Eur J Cancer 2005;41:1889-1910.
13. Chua R, Anderson K, Chen J, Hu M. Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. J Altern Complement Med 2004;10:1053-1060.
14. Hu M, Chen J, Tran D, Zhu Y, Leonardo G. The Caco-2 cell monolayers as an intestinal metabolism model: Metabolism of dipeptide Phe-Pro. J Drug Targ 1994;2:79-89.
15. Hu M, Chen J, Zhu Y, Dantzig AH, Stratford RE, Jr, Kuhfeld MT. Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm Res 1994;11:1405-1413.
16. Liu Y, Hu M. Absorption and metabolism of flavonoids in the Caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos 2002;30:370-377.
17. Griffith AP, Collison MW. Improved methods for the extraction and analysis of isoflavones from soy-containing foods and nutritional supplements by reversed-phase high-performance liquid chromatography and liquid chromatography-mass spectrometry. J Chromatogr A 2001;913(1-2):397-413.
18. Jia X, Chen J, Lin H, Hu M. Disposition of flavonoids via enteric recycling: Enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther 2004;310:1103-1113.
19. Chen J, Wang S, Jia X, Bajimaya S, Tam V, Hu M. Disposition of flavonoids via recycling: Comparison of intestinal versus hepatic disposition. Drug Metab Dispos 2005;33:1777-1784.
20. Nguyen H, Zhang S, Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003;92:250-257.
21. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;304:1258-1267.
22. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-1216.
23. Chen J, Lin H, Hu M. Metabolism of flavonoids via enteric recycling: Role of intestinal disposition. J Pharmacol Exp Ther 2003;304:1228-1235.